Bicalutamide

Catalog No.S1190 Synonyms: ICI-176334

Bicalutamide Chemical Structure

Molecular Weight(MW): 430.37

Bicalutamide is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line.

Size Price Stock Quantity  
In DMSO USD 109 In stock
USD 120 In stock
USD 210 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Immunohistochemical staining of Ki67 was performed to determine cell proliferation in the tumors. Each tissue section was counted manually in three different areas to assess the Ki67-positive cell index. Data were then presented as number of Ki67-positive cells per x 400 microscope field. Results are presented as the means s.d. **P < 0.001 by Student 's t-test, compared with control.

    Oncogene 2014 10.1038/onc.2014.302. Bicalutamide purchased from Selleck.

    (D) Cell apoptosis measured by flow cytometry analysis after cells were exposed to 10μM bicalutamide and 10μM ABT-888 alone or in combination for 48h in MDA-MB-231 and HCC1937. Data are the mean of three independent experiments. *P<0.05, **P<0.01, #P>0.05.

    Int J Biol Sci, 2016, 12(12):1500-1510. Bicalutamide purchased from Selleck.

  • When Tramp-C1 and PTENCaP8 cells were cocultured with macrophages and treated with BMP-6 and dihydrotestosterone simultaneously for 48 h, AR antagonists bicalutamide (Bical) and MDV3100 blocked the androgen hypersensitivity.

    Cancer Sci 2013 104(8), 1027-32. Bicalutamide purchased from Selleck.

    CX4945 resensitizes CRPC cells to anti-androgen therapy. a, b 22Rv1 and VCaP cells were treated with indicated concentration of bicalutamide (Bic) without CX4945. c, d 22Rv1 and VCaP cells were treated with indicated concentration of bicalutamide (Bic) with a subdose of CX4945 (3 or 5 μM). CCK8 assay was performed at 72 h to measure the cell viability. **P < 0.01, ***P < 0.001

    World J Urol, 2017. Bicalutamide purchased from Selleck.

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Biological Activity

Description Bicalutamide is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line.
Targets
Androgen Receptor [1]
(LNCaP/AR(cs) cells)
0.16 μM
In vitro

Bicalutamide undergoes an antagonist-to-agonist switch, stimulating AR activity. Bicalutamide treatment of LNCaP/AR(cs) cells in absence of the synthetic androgen R1881 results in altered gene expression consistent with its well-documented agonist activity in context of AR overexpression. Bicalutamide induces cell proliferation in a dose-dependent manner, and only partially antagonized the effects of R1881. Bicalutamide treatment also results in a significant amount of nuclear AR, although less than that observed with R1881. Bicalutamide exhibits partial agonist activity as evidenced by induction of DNA binding at AR target genes and incomplete antagonism of the effects of R1881. In absence of R1881, Bicalutamide partially activates VP16-AR–mediated transcription, indicative of AR binding to DNA. In LNCaP/AR-luc cells with a stably integrates AR-driven luciferase reporter construct. In the presence of R1881, Bicalutamide shows only weak partial antagonism of VP16-AR–mediated transcription with an IC50 of 0.35 μM. [1] Micromolar bicalutamide causes a significant dose-dependent reduction in clonogenicity. [2] Dual inhibition of the AR and mTOR signaling pathways provides further benefit with the ridaforolimus-bicalutamide combination producing syner -gistic antiproliferative effects in prostate cancer cells in vitro when compared with each agent alone. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-453 cells NIr6Xm5HfW6ldHnvckBie3OjeR?= M2T1S2Rqe3CuYXPlcYVvfCCxZjDbN2heWjF6OEGg[pJwdSCDUjDpckBpfW2jbjDNSGEuVUJvNEWzJINmdGy|LDDFR|UxRTNzIH7N MlzDNlM4OTN3Nke=
LNCaP cells NFTPbYlHfW6ldHnvckBie3OjeR?= NHvSTGxKdmirYnn0bY9vKG:oIGuzTH0uTEiWIHLpcoRqdmdidH:gWFg4P0FiYX7kdo9o\W5icnXj[ZB1d3Jib3[gUG5E[VBiY3XscJMtKEurPUO1JI5O M{\3eFE2PjB|OU[w
Freestyle293F cells NYj3R4x6TnWwY4Tpc44h[XO|YYm= NUfaXI5SUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgRY5lem:pZX6gdoVk\XC2b4KgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hTnKnZYP0fYxmOjl|RjDj[YxteyxiSVO1NF0xNjB3NDFOwG0> M2XXfVI{OTl7NEe3
HEK293 cells NWH2PFd2TnWwY4Tpc44h[XO|YYm= MlH4N{Bp MlTMSIl{eGyjY3Xt[Y51KG:oIGuxO{1idHCqYT3t[ZRpgWxvM1jdcYljd2yncn;u[UBnem:vIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYX\0[ZIhOyCqcoOsJGlEPTB;NUSgcm0> NH7VWoUzOjN7MUCzNy=>
MDA453 cells MX7GeY5kfGmxbjDhd5NigQ>? M3;DSGRqe3CuYXPlcYVvfCCxZjDbN2heTEiWIH\yc40hcHWvYX6gZY5lem:pZX6gdoVk\XC2b4KgbY4hVUSDNEWzJINmdGy|LDDLbV03PCCwTR?= NYPUVmJkOTh{OUG2OFQ>
human MDA-MB-453 cells NIW4e|FHfW6ldHnvckBie3OjeR?= Ml\nSIl{eGyjY3Xt[Y51KG:oIGuzTH1FUFRiZoLvcUBCWiCrbjDoeY1idiCPRFGtUWIuPDV|IHPlcIx{NCCLQ{WwQVY1KG6P MX[yNFU5PDZzMB?=
COS1 cells M3;mVmZ2dmO2aX;uJIF{e2G7 NXP0XGV{SW62YXfvcol{fCCjY4Tpeol1gSCjZ3HpcpN1KHCVR{WteIFo\2WmIHj1cYFvKGGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDDU3MyKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDy[YNmeHSxcj3t[YRq[XSnZDD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYomgRXIuemWpdXzheIVlKHKjdDDwdo9j[XOrbjDwdo9ud3SncjDmdoFodWWwdDDkdol3\W5iZnny[YZtgSCudXPp[oVz[XOnIILldI9zfGW{IHHzd4F6NCCLQ{WwQVAvODh4OTFOwG0> NYSz[lhoOjV4NE[2OFk>
HeLa cells NHz4UGZHfW6ldHnvckBie3OjeR?= MWjBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCKZVzhJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiZHnofYRzd3Snc4Tvd5Rmem:wZTDpcoR2[2WmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCkeTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyPUCuNVQh|ryP MWKxO|gxPDJ{OR?=
CV1 cells MXTGeY5kfGmxbjDhd5NigQ>? MlfuRolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hS1ZzIHPlcIx{NCCNaU2wMlE2OSEQvF2= MUexO|I2Pzh|OB?=
monkey COS7 cells MUjGeY5kfGmxbjDhd5NigQ>? NGm2bnBDcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCvb37r[ZkhS0:VNzDj[YxteyCkeTD3bI9t\SClZXzsJIJqdmSrbnegZZN{[XluIFvpQVAvOTVzIN88US=> NVrFW|A5OTh2NEK5NVI>
COS7 cells M4DFUGZ2dmO2aX;uJIF{e2G7 NY\mfII1SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBYPzRzQzDteZRidnRiZYjwdoV{e2WmIHnuJGNQWzdiY3XscJMh[XO|ZYPz[YQh[XNibIXjbYZmemG|ZTDhZ5Rqfmm2eTDh[pRmeiB{NDDodpMh[nlicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkG4JO69VQ>? M{HlbFIzODl2Mke5
CHO-K1 cells NWPJUmxOTnWwY4Tpc44h[XO|YYm= NEL4U2EzKGh? M{Pl[WRqe3CuYXPlcYVvfCCxZjDbN2hedWmkb3zldo9v\SCocn;tJIh2dWGwIFHSJIV5eHKnc4Pl[EBqdiCFSF:tT|Eh[2WubIOgZYZ1\XJiMjDodpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3ME2wMlIh|ryP NYCwZo5COjB|OEGzOlE>
human HT-3 cell NFz6bZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEjaOmNKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc{OTN2IN88US=> NUTvRpVjW0GQR1XS
human LNCAP cells MVLQdo9tcW[ncnH0bY9vKGG|c3H5 NH;lNm4{KGSjeYO= M17QcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTF7DRXAh[2WubIOgZYZ1\XJiMzDkZZl{NCCLQ{WwQVAvPzN{NzFOwG0> NWO3Spg3OjZyNE[zNVM>
human PC3 cells MXfGeY5kfGmxbjDhd5NigQ>? M4iy[2Rqe3CuYXPlcYVvfCCxZjDbN2heWjF6OEGg[pJwdSCjbnTyc4dmdiC{ZXPldJRweiCrbjDoeY1idiCSQ{OgZ4VtdHNuIFXDOVA:PC5|IN88US=> MnLrNlU2QTFyNk[=
human 22Rv1 cells MoXNSpVv[3Srb36gZZN{[Xl? NHvKV3I{KGSjeYO= NE\VcIVCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHHu[JJw\2WwIILlZ4VxfG:{IFi4O|R[KG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCqdX3hckAzOlK4MTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKESKVD3pcoR2[2WmIHPlcIwh\3Kxd4ToJIFnfGW{IEOg[IF6eyCkeTDXV3QuQCCjc4PhfUwhUUN3ME20MlYh|ryP MVWyOFkxODV6OB?=
human CCF-STTG1 cell Mm\jS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2noUGlvcGmkaYTpc44hd2ZiaIXtZY4hS0OILWPUWGcyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XoxvJygTWM2OD12LkmyPVI6KM7:TR?= M3rGeHNCVkeHUh?=
human SCC-25 cell NV\PZmhTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYPzZY12UW6qaXLpeIlwdiCxZjDoeY1idiCVQ1OtNlUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjB6NkW2JO69VQ>? MoDZV2FPT0WU
human MKN45 cell NF;sPHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHoTY5pcWKrdHnvckBw\iCqdX3hckBOU052NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uPVYxPSEQvF2= MlH6V2FPT0WU
human ES5 cell M{\PdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{DKPGlvcGmkaYTpc44hd2ZiaIXtZY4hTVN3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OD62NVE2PCEQvF2= M4DHZXNCVkeHUh?=
human SK-MEL-3 cell NWKzZYw3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEe2OGhKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTBwMEm2OEDPxE1? NXrQVIlRW0GQR1XS
human PC-3 cell MmTzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4ru[GlvcGmkaYTpc44hd2ZiaIXtZY4hWENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlI4QTFizszN NYTteWZlW0GQR1XS
human NOS-1 cell Mlm4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MULJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGuNlkyPyEQvF2= Mo\uV2FPT0WU
human LB1047-RCC cell M2XYfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWPyPZNyUW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUKuNlU{KM7:TR?= M{DYb3NCVkeHUh?=
human CAMA-1 cell M1PQd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHK0U|NKdmirYnn0bY9vKG:oIHj1cYFvKEODTVGtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzNjN7Mk[g{txO MXXTRW5ITVJ?
human SAS cell NF2zTXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmDjTY5pcWKrdHnvckBw\iCqdX3hckBUSVNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMz6zNFgyKM7:TR?= MXjTRW5ITVJ?
human NCI-H2228 cell NHm0RmJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWW3d5Z[UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIzOjhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMz63OVMyKM7:TR?= MVrTRW5ITVJ?
human NCI-H187 cell NUXDOW9uT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUi3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPjZzNjFOwG0> MWXTRW5ITVJ?
human BFTC-905 cell MmTZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUHL[mRzUW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF5LkS4OVch|ryP M3\0UXNCVkeHUh?=
human G-361 cell NG\3dW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoLqTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG3MlgzPiEQvF2= MnjzV2FPT0WU
human DU145 cells M4XEWGN6fG:2b4jpZ:Kh[XO|YYm= NX7oNYZZPzJiaB?= MljLR5l1d3SxeHnjbZR6KGGpYXnud5QhTVKjbIDoZU1l\W[rY3nlcpQhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCHUnLleIEh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yQCEQvF2= Mn\kV2FPT0WU
human SW780 cell M2[3PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3LKbWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfS=> NHHae|lUSU6JRWK=
human BB49-HNC cell MnPmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWLIcpRuUW6qaXLpeIlwdiCxZjDoeY1idiCEQkS5MWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF6Lkm1N|Ih|ryP NGLFe3NUSU6JRWK=
human KALS-1 cell NFLDPZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkLOTY5pcWKrdHnvckBw\iCqdX3hckBMSUyVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPU43PjN3IN88US=> M1PrbnNCVkeHUh?=
human AU565 cell Ml\WS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGFWPTZ3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUmuO|QxOiEQvF2= NFvybZBUSU6JRWK=
human NCI-H2087 cell NH7jTHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjiT2kxUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQDdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MT6wOVkyKM7:TR?= M17mT3NCVkeHUh?=
human RVH-421 cell NWXjfI53T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXjJcohq[mm2aX;uJI9nKGi3bXHuJHJXUC12MkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU42Pzl3IN88US=> M2HGUHNCVkeHUh?=
human SK-CO-1 cell M4DFd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWT6bJFWUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3DU{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjFwOEi3NkDPxE1? M12wcnNCVkeHUh?=
human KU-19-19 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoDmTY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIzNjB{NEKg{txO M13pbHNCVkeHUh?=
human NB6 cell MlW2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2HpZWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkKuPVE{PSEQvF2= M13rbHNCVkeHUh?=
human RO82-W-1 cell M{TEUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXrJcohq[mm2aX;uJI9nKGi3bXHuJHJQQDJvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlMvOTNzODFOwG0> M3\kTnNCVkeHUh?=
human LNCAP cells NHf5XmhEgXSxdH;4bYPDqGG|c3H5 NF3xfGUzKGSjeYO= MlTpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgNkBl[Xm|IHL5JINmdGxiY3;1cpRqdmdibXX0bI9lNCCLQ{WwQVI{Njd7IN88US=> M1TydFI{PzJ5MES0
human CTB-1 cell NETCc|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3f0PWlvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE42PTN4IN88US=> NYj6fXN[W0GQR1XS
human SW48 cell M4i3PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKGi3bXHuJHNYPDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{ND62OVQ3KM7:TR?= NWj0THUzW0GQR1XS
human TCCSUP cell M4TWdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmH1TY5pcWKrdHnvckBw\iCqdX3hckBVS0OVVWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE44OjN{IN88US=> M1vLR3NCVkeHUh?=
human DK-MG cell Mmf2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHfmZlZKdmirYnn0bY9vKG:oIHj1cYFvKESNLV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvQDlzNzFOwG0> MVnTRW5ITVJ?
human ST486 cell NXzuOFdvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYDJcohq[mm2aX;uJI9nKGi3bXHuJHNVPDh4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkWuO|Q3PCEQvF2= Mk\hV2FPT0WU
human H4 cell NEjKfIVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoDQTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJ4Lkm0OVgh|ryP MV\TRW5ITVJ?
human SBC-1 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NImyZWRKdmirYnn0bY9vKG:oIHj1cYFvKFOEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvOzVyNzFOwG0> MkHqV2FPT0WU
human CAS-1 cell MnHmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mm\KTY5pcWKrdHnvckBw\iCqdX3hckBESVNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK4MlYzQTRizszN NEXGdnRUSU6JRWK=
human OAW-42 cell M{TTcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX3xS5JxUW6qaXLpeIlwdiCxZjDoeY1idiCRQWetOFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zQC55MUm1JO69VQ>? NYjWRXc4W0GQR1XS
human HCC1954 cell MnrFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4LTcmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUm1OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5Njd3MkWg{txO MVfTRW5ITVJ?
human MDA-MB-453 cell MmrWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;C[IRKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk01PTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{OT65NFch|ryP MVXTRW5ITVJ?
human MCF7 cell NIXre3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUfJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|OT6zNFEh|ryP M1nzXHNCVkeHUh?=
human PC3 cells NGPye2xHfW6ldHnvckBie3OjeR?= M2PaO|ExOOPCgN88US=> NUXPZXJ4PDhiaB?= M4jp[GlvcGmkaYTpc44hd2ZiYXP0bY4h[mG|ZXSgdJNmfWSxcH;kbYEh\m:{bXH0bY9vKGmwIHHu[JJw\2WwLXTldIVv\GWwdDDoeY1idiCSQ{OgZ4VtdHNiYYSgNVAxKHWPIHHmeIVzKDR6IHjyd{BjgSCGQWDJJJN1[WmwaX7nJIJie2WmIH\seY9z\XOlZX7j[UBucWO{b4Pjc5B6KGG|c3H5 M4fOWFIzPjd{OUi0
human PC3 cells NH3KPVFHfW6ldHnvckBie3OjeR?= NXjnXJl7OC5zLUGg{txO Mn\pRYdwdmm|dDDhZ5Rqfmm2eTDheEBidmS{b3flckBz\WOncITvdkBYPzRzQzDteZRidnRiZYjwdoV{e2WmIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{B{fGmvdXzheIlwdiCxZjDy[YNmeHSxcjD0doFve2GldHn2ZZRqd25iYYSgNE4yKHSxIEGgeW0h[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 MWqyNlE4PTZ7NB?=

... Click to View More Cell Line Experimental Data

In vivo Single bicalutamide reduces tumor growth by 79%, at defined submaximal doses. The ridaforolimus-bicalutamide combination exhibits improved and potent antitumor activity, almost completely abrogating tumor growth. The combination is also well tolerated, as evidenced by no significant changes in body weight over the course of treatment. Plasma PSA levels are again tightly linked to tumor growth in the combination-treated mice. [3]

Protocol

Kinase Assay:[1]
+ Expand

Whole-cell competitive binding assays:

Whole-cell competitive binding assays are performed in LNCaP/AR(codon-switch) (LNCaP/AR(cs)) (harbors a mixture of exogenous wild-type AR and endogenous mutant AR (T877A)) and cells propagated in Iscove's or RPMI media supplemented with 10% fetal bovine serum, or during the assay with 10% charcoal-stripped, dextran-treated fetal bovine serum (CSS). Cells are pre-incubated with 18F-FDHT, increasing concentrations (1pM to 1μM) of cold Bicalutamide are added, and the assay is performed to measure specific uptake of 18F-FDHT (4). IC50 values are determined using a one site binding model with least squares curve fitting and R2 > 0.99.
Cell Research:[3]
+ Expand
  • Cell lines: C4-2 cell
  • Concentrations: 0-1 μM
  • Incubation Time: 72 hours
  • Method: Exponentially growing C4-2 cells are plated into two 96-well plates and incubated overnight at 37 ˚C. Twenty-four hours later one plate is aspirated and stored at -80 ˚C and the other treated with 10-fold serial concentrations of ridaforolimus (1000 nM to 0.0001 nM) or vehicle (ethanol). Following 72 hours culture at 37 ˚C, the plates are assessed simultaneously for cell growth using the Cy qUANT Cell Proliferation Assay kit. Bicalutamide and Ridaforolimus combination proliferation assays are performed similarly except cell growth is determined as the change in cell number between vehicle control and compound treated cells after 72 hours in culture.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: Male nude mice bearing C4-2 cells
  • Formulation: 4% ethanol, 5% Tween 80, and 5% propylene glycol
  • Dosages: 10 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (199.82 mM)
Ethanol 5 mg/mL (11.61 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 430.37
Formula

C18H14F4N2O4S

CAS No. 90357-06-5
Storage powder
Synonyms ICI-176334

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03043807 Not yet recruiting Prostate Cancer Sidney Kimmel Comprehensive Cancer Center February 2017 Phase 2
NCT02716974 Recruiting Prostate Cancer Sidney Kimmel Comprehensive Cancer Center June 2016 Phase 2
NCT02582749 Recruiting Prostate Cancer|Bone Metastases|Prostate Neoplasms Ajjai Alva, MD|Hoosier Cancer Research Network|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma April 2016 Phase 2
NCT02742675 Recruiting Prostate Cancer Fudan University March 2016 Phase 2
NCT02697032 Recruiting Breast Cancer University Medical Center Groningen February 2016 Phase 2
NCT02910050 Recruiting Breast Cancer Xu fei|Sun Yat-sen University January 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Androgen Receptor Signaling Pathway Map

Related Androgen Receptor Products

Tags: buy Bicalutamide | Bicalutamide ic50 | Bicalutamide price | Bicalutamide cost | Bicalutamide solubility dmso | Bicalutamide purchase | Bicalutamide manufacturer | Bicalutamide research buy | Bicalutamide order | Bicalutamide mouse | Bicalutamide chemical structure | Bicalutamide mw | Bicalutamide molecular weight | Bicalutamide datasheet | Bicalutamide supplier | Bicalutamide in vitro | Bicalutamide cell line | Bicalutamide concentration | Bicalutamide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID